Capitol Health (ASX:CAJ) secured shareholder approval on Monday relating to the company's proposed merger with Integral Diagnostics (ASX:IDX) through a scheme of arrangement, according to a same-day filing with the Australian bourse.
About 95% of the shareholders were present and voting during the meeting with 99.9% of all votes in favor of the resolution, the filing said.
Integral Diagnostics has been engaged with the Australian Competition and Consumer Commission regarding the potential divestment and is awaiting informal merger clearance from the regulator.
Once Integral Diagnostics receives merger clearance from the Australian Competition and Consumer Commission, the company will apply to the Court for approval of the scheme.
Earlier, Capitol Health said the Federal Court of Australia will hear on Dec. 4 its application seeking the approval of the scheme.
Shares of Capitol Health and Internal Diagnostics each fell 3% on market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。